Adding daratumumab to myeloma regimens may improve outcomes in high-risk MM
Incorporating daratumumab to established myeloma regimens in patients with newly diagnosed high-risk MM (HRMM) may be linked with improved progression free survival (PFS) in newly diagnosed patients as well as those with relapsed/refractory HRMM, according to a study in JAMA Oncology.
In this systematic review and meta-analysis, 6 phase 3 trials (3 trials for newly diagnosed MM and 3 trials for relapsed/refractory HRMM) were included.
The addition of daratumumab to established myeloma regimens in patients with newly diagnosed HRMM and among patients with relapsed or refractory HRMM was associated with improved PFS (pooled HR, 0.67; 95% CI, 0.47-0.95; P = 0.02 and pooled HR, 0.45; 95% CI, 0.30-0.67; P < 0 .001, respectively.) Little evidence of heterogeneity was found in either instance.
Giri S, Grimshaw A, Bal S, et al. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. JAMA Oncol. doi:10.1001/jamaoncol.2020.4338